Markets:

Overview

News

Currencies

International

Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.44 -1.44 (-5.56%)

Streaming Delayed Price Updated: 11:35 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 08, 2025

Via Benzinga

Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice ↗

April 08, 2025

As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030.

Via Stocktwits

Topics Intellectual Property Lawsuit

Wondering what's happening in today's after-hours session? ↗

April 07, 2025

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 07, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts ↗

February 28, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

April 07, 2025

From Pacira BioSciences

Via GlobeNewswire

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. ↗

April 05, 2025

PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

April 03, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

April 01, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

March 14, 2025

From Pacira BioSciences

Via GlobeNewswire

PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX

March 13, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

PACIRA BIOSCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Pacira BioSciences, Inc. - PCRX

March 11, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

March 11, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

March 09, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX

March 07, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2025

From Pacira BioSciences

Via GlobeNewswire

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

March 05, 2025

From SkyMedia, LLC

Via GlobeNewswire

3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX ↗

March 05, 2025

The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility.

Via Talk Markets

Topics Stocks / Equities

PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

March 04, 2025

From Kahn Swick & Foti, LLC

Via GlobeNewswire

PCRX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX

March 03, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

March 03, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

February 28, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

PCRX STOCKHOLDERS: Contact Robbins LLP for Information About the Pacira BioSciences, Inc. Class Action Before the Expiration of the Lead Plaintiff Deadline

February 27, 2025

From Robbins LLP

Via GlobeNewswire

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

February 27, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

February 27, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March

February 26, 2025

From Pacira BioSciences

Via GlobeNewswire

For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals. ↗

February 25, 2025

PACIRA BIOSCIENCES INC has a stellar value proposition. NASDAQ:PCRX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

Via Chartmill

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

February 24, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

February 21, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.